Biotech Values

[Whalatane]

UNCY ...my pitch
First this is a risk only what you can afford to lose spec. Trial failure ...to many dropping OLC due to side effects especially nausea and PPS will be at least cut in half ...JMO
Upside potential ...for what it's worth

-Piper Sandler Initiates Coverage on Unicycive Therapeutics With Overweight Rating, $9 Price Target

. earlier this mth
Background ...dialysis patients hate the current serum phosphorous binders ...usually large pills that have to be chewed with each meal and taste terrible .
Compliance is poor ....most are no where near goal
ARDX has introduced a new drug Xpanzoh but the patient co pay is roughly $1,000 a month and almost half have problems with diarrhea ...which pass's over time
Now comes OLC which is a " condensed " version of Fosrenol and FDA agrees is bioequivlent to Fosrenol .

The case for OLC .
The biggest patient complaint for the available serum phosphorous binders is pill burden and taste .
OLC is one small pill with each meal that is swallowed not chewed or in powder form.
The final trial ...ending about now is Open Labelled . It's testing tolerability ...how many will drop out due to AE's .
Historically the dropout rate for this type of binder ( Lanthanum Carbonate ...brand name Fosrenol ) is usually between 10-15% in the titration phase and less in the maintenance phase .
This is in the chewed form .
AE's have been higher when patients swallowed Fosrenol rather then chewed it ...and OLC is swallowed .

Final trial data due I expect in May
Do your own DD etc etc
Kiwi